GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2011

Cardio3 Establishes U.S. Subsidiary in Advance of Phase III Heart Failure Cell Therapy Trial

  • Belgian cardiac cell therapies firm Cardio3 BioSciences established a U.S. subsidiary in Rochester, MN, to support its clinical and development activities and to bolster existing links with the Mayo Clinic and other U.S. collaborators. Cardio3’s lead product, C3BS-CQR-1 (C-Cure®), is a stem cell-based cardiac lineage in clinical development for the treatment of heart failure. Phase III studies are projected to start in 2012.

    Having a base in the U.S. will allow the firm to substantiate early evidence of the feasibility, safety, and efficacy of C-Cure in a larger-scale setting, including Phase III studies, and strengthen its ongoing research and commercialization relationship with the Mayo Clinic, which developed the cardiopoiesis technology on which Cardio3’s platform has been built.

    Founded in 2007, Cardio3 is focused on the development of regenerative and protective therapies for the treatment of cardiac disease. Lead product candidate C-Cure is based on a patient’s own bone marrow stem cells, which are treated with a cardiopoietic cocktail before being re-injected into the heart to generate heart muscle cells. The firm says the treatment acts both directly, through the proliferation, engraftment, and terminal differentiation of the injected cells, as well as indirectly, through the beneficial effect on the patient’s existing cardiac stem cells of factors secreted by the transplanted cells.

    Positive six-month data from a Phase II trial in heart failure patients were reported in November 2010. The study, in Belgium, Serbia, and Switzerland, showed that patients treated using C-Cure in addition to standard care demonstrated significant increases in left ventricular ejection fraction over and above those treated in the control group. Data also suggested that the treatment led to favorable heart muscle remodeling, improved heart muscle performance, and led to improved fitness. Bone marrow from 70% of 30 patients was successfully processed into C-Cure; Cardio3 says it aims to increase this to 80% in its Phase III clinical program.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »